The great challenge is even if human growth development will lengthen the outer frontier of human continuation. Many analyst contest that the greatest life span is not fixed. With advancing expertise, such as the capacity to engineer the genes at will. They will drive back the edge to 150 years and past interventions like human growth hormone will permit us to live long enough so that the new-found interventions that will reach the next leap in life span will be on board.
But whereas the confirmation is very preliminary, there are certain clear indicators that GH possibly will not only lengthen the quality of life but the quantity as well. At present, the only viable way to test a life span intervention is to apply a short lived animal species, if possible a mammal, which bears about resemblance to the human position. In 1990, two examiner at North Dakota State University go after to answer this challenge. They gave IGF-1 infections to a company to twenty-six mice that were seventeen months old, or other that three-quarters by way of their average life span of twenty-one months. The animals were exhibit symptoms of aging and members of the primary colony of sixty mice had begun to expire .
A control collection of twenty-six mice that were the same age obtained placebo infections of saline solution. After thirteen weeks, sixteen animals, or 61 percent in the control grouping has died, while all but two, or 97 percent, of the human growth development treated animal were yet alive! In other words, the vast majority of the treated animals had already lived lengthened than the life expectancy for that species.
At this position in the test, the examiner sacrificed four animals from every group to look at their immune function. The left over mice were reserved alive untreated for a further four weeks. Throughout this period, the control collection had entirely died out, while lone one mouse from the hormone treated group died. The scientist resumed hormonetherapy for an extra six weeks until they had consume their resource of GH and were required to close the testing. Sacrificing all the animals. Only one mouse died through this interval of the research. This means that absent of the original group of 26 treated mice, no more than four mice died of uncontrolled causes.
This left 18 mice who were yet alive 22 weeks following therapy had begun, while the full control group had died entirely after 16 weeks. The after-effects, say the examiner, say that long term human growth development therapy lengthen the average life expectation of the hormone treated mice significantly.